You are here

Programme at a Glance - EASD Annual Meeting 2023

All times shown are CEST - Central European Summer Time

Tuesday, 3 October 2023

 

Hamburg
Hall

London
Hall

Paris
Hall

Barcelona
Hall

Mumbai
Hall

Lima
Hall

Cairo
Hall

Spotlight
Stage

09:00
09:30

Presidential Address

       

09:30
10:15

55th Claude Bernard Lecture

       

10:30
12:00

OP 1

OP 2

OP 3

OP 4

OP 5

OP 6

OP 7

 

12:30
13:30

Short Oral Discussions - Event A

 

Debate: Initial combined therapy for type 2 diabetes: Should diabetes follow hypertension?

13:45
14:45

Short Oral Discussions - Event B

 

The 1-hour plasma glucose as a novel biomarker for detecting dysglycaemia, complications and mortality

15:15
16:45

OP 8

OP 9

OP 10

OP 11

OP 12

OP 13

OP 14

 

17:15
18:15

38th Camillo Golgi Lecture

Showcasing EASD’s future: an EASD Academy Symposium

SGLT2 inhibitors and GLP-1 receptor agonist: mechanisms of beneficial action beyond glycaemic control

Healing the feelings in type 1 diabetes

Understanding and treating severe insulin resistance with lipodystrophy

Stay tuned for optimal circadian rhythms and glucose control!

Islet cross-talk in endocrine hormone regulation

 

Wednesday, 4 October 2023

 

Hamburg
Hall

London
Hall

Paris
Hall

Barcelona
Hall

Mumbai
Hall

Lima
Hall

Cairo
Hall

Spotlight
Stage

09:00
10:30

Obesity heterogeneity: clinical aspects

17th Albert Renold Lecture
(09:00 - 10:00)

 

The evolving enigma of type 1 diabetes

Cystic fibrosis derived diabetes from clinic to research and back

 

EASD/JDRF Symposium: Are youth with diabetes at risk for cardiovascular disease?

 

10:45
12:15

OP 15

OP 16

OP 17

OP 18

OP 19

OP 20

OP 21

 

12:45
13:45

Short Oral Discussions - Event C

EFSD/Novo Nordisk Foundation Future Leaders Symposium

 

14:00
15:00

Short Oral Discussions - Event D

  

15:30
17:00

OP 22

OP 23

OP 24

OP 25

OP 26

OP 27

OP 28

 

17:30
18:30

EASD/Novo Nordisk Foundation Diabetes Prize for Excellence Lecture

Michael Berger Debate: Is it time to reclassify diabetes complications because microvascular and macrovascular classification is no longer sufficient?

Debate: Should non-insulin-treated women with diabetes during pregnancy be offered Continuous Glucose Monitoring?

Obesity and cachexia: Two sides of the same coin?

Diabetic retinopathy biomarkers and treatment targets from discovery to the clinic

NAFLD and diabetes: chicken or egg?

 

 

18:45
19:45

 

 

 

 

 

 

EASD General Assembly

 

Thursday, 5 October 2023

 

Hamburg
Hall

London
Hall

Paris
Hall

Barcelona
Hall

Mumbai
Hall

Lima
Hall

Cairo
Hall

Spotlight
Stage

09:00
10:30

Diabetologia Symposium: Incredible incretins - and where to find them

What have cohort studies taught us about the natural history of type 2 diabetes?

 Rising Star Symposium
(08:50 - 10:30)

 Image-in' what noninvasive techniques can do for diabetes research and care!

Metabolic disease and the circle of life

7th EASD-AASD Joint Symposium:
Can COVID-19 help us deliver a whole system holistic healthcare?

Precision medicine in diabetes: complexity and pragmatism

 

10:45
12:15

OP 29

OP 30

OP 31

OP 32

OP 33

OP 34

OP 35

 

12:45
13:45

Short Oral Discussions - Event E

 

Towards independence in diabetes research: an EASD Academy Symposium

14:00
15:00

Short Oral Discussions - Event F

  

15:30
17:00

OP 36

OP 37

OP 38

OP 39

OP 40

OP 41

OP 42

 

17:30
18:30

Induction of Honorary Members

58th Minkowski Lecture
(17:30 - 18:15)

‘With a little help from my friends’: What can we learn from other specialities?

 

Adipose tissue heterogeneity: cellular and molecular aspects

Sweet Odyssey 2022: computing optimal care for complications

   

Friday, 6 October 2023

 

Hamburg
Hall

London
Hall

Paris
Hall

Barcelona
Hall

Mumbai
Hall

Lima
Hall

Cairo
Hall

Spotlight
Stage

09:00
10:00

EASD-Lilly Centennial Anniversary Prize Lecture
(09:00 - 09:45)

Current status on stem cell derived islets: Ready for the clinic?

Turning down the thermostat for metabolic health!

Debate: SGLT- 2 or not 2 that is the question? All people with diabetes and CKD should be on SGLT-2 Inhibition by default

EASD/ESC Symposium: Does increased glucose variability harm the vessels or organs?

Sexual orientation, gender identity and cardiometabolic risk

Treatment strategies to prevent or attenuate renal impairment in type 2 diabetes

 

10:30
11:30

OP 43

OP 44

OP 45

OP 46

OP 47

OP 48

OP 49

 

12:00
13:00

OP 50

OP 51

OP 52

OP 53

OP 54

OP 55

OP 56

 

13:30
15:00

 

 

Facing the unexpected: how to fight diabetes while fighting the war or disaster…

Diabetic neuropathy from genetics to clinical practice

The old and the new risk factors for diabetic kidney disease

Brain control of islet function

Cognition and related conditions in diabetes


 

Please note that the programme may be subject to change.